Immunocore Limited announced the appointment of Andrew Hotchkiss as Chief Commercial Officer (CCO). Andrew joins company from Eli Lilly & Co, where he held a number of global leadership positions across multiple therapeutic areas and geographies including as Vice President International Business Unit Leader Oncology and President Biomedicines Business Units, Australia, Canada and Europe. Andrew will be based at company's headquarters in Oxford, UK and, as CCO, will oversee company's global commercial operations and the preparation of the implementation of the company's future commercial strategy.